Advanced search
Publication Cover
Bioengineered Volume 12, 2021 - Issue 2
Submit an article Journal homepage
4,718
Views
2
CrossRef citations to date
0
Altmetric
Research Paper

Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery

Lipei Wua Department of Laboratory Medicine, Dongtai People’s Hospital & Dongtai Hospital of Nantong University, Yancheng, P.R. China;b Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, P.R. ChinaView further author information
,
Weiwei Wangc Department of Pathology, Tinghu People’s Hospital, Yancheng, P.R. ChinaView further author information
,
Jiale Tianb Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, P.R. ChinaView further author information
,
Chunrun Qic Department of Pathology, Tinghu People’s Hospital, Yancheng, P.R. ChinaView further author information
,
Zhengxin Caid Department of Laboratory Medicine, Tinghu People’s Hospital of Yancheng City, Yancheng, P.R. ChinaView further author information
,
Wenhui Yand Department of Laboratory Medicine, Tinghu People’s Hospital of Yancheng City, Yancheng, P.R. ChinaView further author information
,
Shihai Xuana Department of Laboratory Medicine, Dongtai People’s Hospital & Dongtai Hospital of Nantong University, Yancheng, P.R. ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4786-4143View further author information
ORCID Icon &
Anquan Shangb Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, P.R. ChinaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 12383-12393 | Received 08 Oct 2021, Accepted 03 Nov 2021, Published online: 13 Dec 2021

References

  • Leavy O. Therapeutic antibodies: past, present and future. Nat Rev Immunol. 2010;10(5):297.
  • Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003;38:419–425.
  • Parren PWHI, Lugovskoy AA. Therapeutic antibody engineering: current and future advances driving the strongest growth area in the pharmaceutical industry. MAbs. 2013;5:175–177.
  • Stadler CR, Bähr-Mahmud H, Celik L, et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017 Jul;23(7):815–817.
  • Pardi N, Secreto AJ, Shan X, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630.
  • Kose N, Fox JM, Sapparapu G, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol. 2019;4:eaaw6647.
  • Van Hoecke L, Roose K. How mRNA therapeutics are entering the monoclonal antibody field. J Transl Med. 2019;17:54.
  • Arya S, Lin Q, Zhou N, et al. Strong immune responses induced by direct local injections of modified mRNA-Lipid nanocomplexes. Mol Ther Nucleic Acids. 2020;19:1098–1109.
  • Ickenstein LM, Garidel P. Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opin Drug Deliv. 2019;16:1205–1226.
  • Yu A M, Choi YH, Tu M J. RNA drugs and RNA targets for small molecules: principles, progress, and challenges. Pharmacol Rev. 2020;72(4):862–898.
  • Rybakova Y, Kowalski PS, Huang Y, et al. mRNA delivery for therapeutic Anti-HER2 antibody expression In Vivo. Mol Ther. 2019;27(8):1415–1423.
  • Guevara ML, Persano F, Persano S. Advances in lipid nanoparticles for mRNA-Based cancer immunotherapy. Front Chem. 2020;8:589959.
  • Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev. 2020;154-155:37–63.
  • Miliotou AN, Papadopoulou LC. In Vitro-Transcribed (IVT)-mRNA CAR therapy development. Methods Mol Biol. 2020;2086:87–117.
  • Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–351.
  • Kamura T, Katsuda Y, Kitamura Y, et al. G-quadruplexes in mRNA: a key structure for biological function. Biochem Biophys Res Commun. 2020;526:261–266.
  • Rauch S, Lutz J, Kowalczyk A, et al. RNActive® technology: generation and testing of stable and immunogenic mRNA vaccines. Methods Mol Biol. 2017;1499:89–107.
  • Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.
  • Sun L, Li CW, Chung EM, et al. Targeting glycosylated PD-1 induces potent antitumor immunity. Cancer Res. 2020;80:2298–2310.
  • Schlake T, Thran M, Fiedler K, et al. mRNA: a novel avenue to antibody therapy? Mol Ther. 2019 Apr 10;27(4):773–784.
  • Reichmuth AM, Oberli MA, Jaklenec A, et al. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7:319–334.
  • Stadler CR, Bähr-Mahmud H, Celik L, et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017;23:815–817.
  • Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13:759–780.
  • Li J, Gong YM, Wu J, et al. Anti-tumor necrosis factor-α monoclonal antibody alleviates parenteral nutrition-associated liver disease in mice. JPEN J Parenter Enteral Nutr. 2012;36:219–225.
  • Trepotec Z, Lichtenegger E, Plank C, et al. Delivery of mRNA therapeutics for the treatment of hepatic diseases. Mol Ther. 2019;27:794–802.
  • Huang H, Zhang C, Yang S, et al. The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2. J Control Release. 2021;335:449–456.
  • Tiwari PM, Vanover D, Lindsay KE, et al. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat Commun. 2018;9:3999.
  • Kowalski PS, Rudra A, Miao L, et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710–728.
  • Hu W, Kaminski R, Yang F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA. 2014;111:11461–11466.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.